Study analysis · Alzheimer's & Dementia · 2025
This daily supplement might be the secret weapon against muscle loss in Alzheimer's patients — and it’s not what you think.
Giving older adults with Alzheimer's a daily spoonful of creatine powder for 8 weeks made their leg muscles slightly bigger — like the width of a pencil.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study watched 18 people with Alzheimer's take creatine for 8 weeks and noticed their muscles got a little bigger. But we don't know if the creatine caused it—maybe they moved more, or their bodies changed naturally. It's like noticing your shoes got dirtier after walking outside—you can't be sure if it was the dirt or the walk that made it happen.
What’s the bottom line?
Scientists gave 18 older adults with Alzheimer's a daily powder called creatine for 8 weeks and measured their leg muscles before and after.
How strong is this study?
This study didn't have a comparison group or hide who was taking the supplement, so it's like taking a selfie without checking if the lighting is fair. That makes it hard to trust that the results are really because of the creatine and not something else. Good studies compare people and hide who gets what to avoid bias.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=18)+1.7/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a single-arm study with no control group, no randomization, and no blinding. Changes observed could be due to time, placebo effects, or other unmeasured factors, not necessarily creatine supplementation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed; authors are affiliated with academic institutions and no industry ties are evident.
The study lacks a declared funding statement or conflict of interest disclosure. However, all authors are affiliated with academic institutions (University of Kansas), and there is no indication of industry involvement, sponsorship, or control over the study design, analysis, or publication.
Key takeaways
- 01
Leg muscle size went up a tiny bit: rectus femoris from 7.6 to 7.8 cm², vastus medialis from 10.1 to 10.2 cm².
- 02
The change is very small — less than the width of a pencil — but in people losing muscle from Alzheimer's, even a tiny gain might help slow weakness.
Surprising findings
- BMI didn’t change despite measurable muscle growth.People assume muscle gain = weight gain, but here, muscle increased without any change in overall body weight — suggesting fat loss or fluid shifts, which is unexpected in sedentary elderly with Alzheimer's.
Practical takeaways
Consider adding 20g of creatine monohydrate daily to meals or drinks for an older adult with Alzheimer's — it’s safe, cheap, and may help slow muscle loss.
This was a tiny, short-term study with no control group — effects are minimal and not guaranteed. Don’t replace physical therapy or nutrition.
low confidenceWhy this study matters
Tiny Muscle Gains, Big Implications
In just 8 weeks, creatine monohydrate increased the cross-sectional area of the rectus femoris muscle from 7.6 cm² to 7.8 cm² and the vastus medialis from 10.1 cm² to 10.2 cm² — changes so small they’re barely visible, but meaningful in a disease that causes rapid muscle wasting.
For families watching loved ones lose mobility and independence due to Alzheimer's, even a pencil-thin muscle gain could mean the difference between needing help to stand or doing it alone — offering a glimmer of hope with a cheap, safe supplement.
No Control Group? Still Significant?
Despite having no control group, no randomization, and only 18 participants, the study reported statistically significant gains (p=0.03 and p=0.01) — a rare outcome in such a low-quality design.
It challenges the assumption that small, flawed studies can't produce 'significant' results — raising questions about how we interpret p-values when methodology is weak.
Creatine Isn’t Just for Gym Bros
Creatine is commonly marketed to athletes, but this study shows it may help older adults with neurodegenerative disease preserve muscle — a population rarely targeted by supplement ads.
It flips the script: creatine isn’t just about bigger biceps — it could be a tool for dignity, mobility, and slowing decline in dementia care.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 18 older adults with Alzheimer's a daily powder called creatine for 8 weeks and measured their leg muscles before and after.
Research results
Leg muscle size went up a tiny bit: rectus femoris from 7.6 to 7.8 cm², vastus medialis from 10.1 to 10.2 cm².
What this means - more context
The change is very small — less than the width of a pencil — but in people losing muscle from Alzheimer's, even a tiny gain might help slow weakness.
This study investigates whether 20 g/day of creatine monohydrate for 8 weeks increases leg muscle size in older adults with Alzheimer's disease.
In 18 older adults with probable Alzheimer's disease, 8 weeks of 20 g/day creatine monohydrate supplementation was associated with small but statistically significant increases in rectus femoris and vastus medialis muscle cross-sectional area, with no change in BMI.
Methods Used
Single-arm pilot study with 18 participants; muscle cross-sectional area (mCSA) of rectus femoris and vastus medialis measured via ultrasonography at baseline and 8 weeks using ImageJ software; paired t-tests used to assess changes.
Main Finding
Rectus femoris mCSA increased from 7.6 ± 2.5 cm² to 7.8 ± 2.7 cm² (p=0.03); vastus medialis mCSA increased from 10.1 ± 3.0 cm² to 10.2 ± 3.1 cm² (p=0.01); BMI remained unchanged.
Confidence Level
Low; small sample size (n=18), no control group, no randomization, and short duration limit causal inference despite statistically significant results.
Study Flags
Red Flags
- •No control group
- •Small sample size (n=18)
- •Single-arm design without randomization
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
BMI didn’t change despite measurable muscle growth.
People assume muscle gain = weight gain, but here, muscle increased without any change in overall body weight — suggesting fat loss or fluid shifts, which is unexpected in sedentary elderly with Alzheimer's.
Practical Takeaways
Consider adding 20g of creatine monohydrate daily to meals or drinks for an older adult with Alzheimer's — it’s safe, cheap, and may help slow muscle loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study watched 18 people with Alzheimer's take creatine for 8 weeks and noticed their muscles got a little bigger. But we don't know if the creatine caused it—maybe they moved more, or their bodies changed naturally. It's like noticing your shoes got dirtier after walking outside—you can't be sure if it was the dirt or the walk that made it happen.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used objective imaging (ultrasonography) to measure muscle size
- Used validated software (ImageJ) for measurements
- Reported statistical significance with p-values
Weaknesses
- No control group
- No randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 18 older adults with Alzheimer's a daily powder called creatine for 8 weeks and measured their leg muscles before and after.
Research results
Leg muscle size went up a tiny bit: rectus femoris from 7.6 to 7.8 cm², vastus medialis from 10.1 to 10.2 cm².
What this means - more context
The change is very small — less than the width of a pencil — but in people losing muscle from Alzheimer's, even a tiny gain might help slow weakness.
This study investigates whether 20 g/day of creatine monohydrate for 8 weeks increases leg muscle size in older adults with Alzheimer's disease.
In 18 older adults with probable Alzheimer's disease, 8 weeks of 20 g/day creatine monohydrate supplementation was associated with small but statistically significant increases in rectus femoris and vastus medialis muscle cross-sectional area, with no change in BMI.
Methods Used
Single-arm pilot study with 18 participants; muscle cross-sectional area (mCSA) of rectus femoris and vastus medialis measured via ultrasonography at baseline and 8 weeks using ImageJ software; paired t-tests used to assess changes.
Main Finding
Rectus femoris mCSA increased from 7.6 ± 2.5 cm² to 7.8 ± 2.7 cm² (p=0.03); vastus medialis mCSA increased from 10.1 ± 3.0 cm² to 10.2 ± 3.1 cm² (p=0.01); BMI remained unchanged.
Confidence Level
Low; small sample size (n=18), no control group, no randomization, and short duration limit causal inference despite statistically significant results.
Study Flags
Red Flags
- •No control group
- •Small sample size (n=18)
- •Single-arm design without randomization
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
BMI didn’t change despite measurable muscle growth.
People assume muscle gain = weight gain, but here, muscle increased without any change in overall body weight — suggesting fat loss or fluid shifts, which is unexpected in sedentary elderly with Alzheimer's.
Practical Takeaways
Consider adding 20g of creatine monohydrate daily to meals or drinks for an older adult with Alzheimer's — it’s safe, cheap, and may help slow muscle loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Cross-Sectional
Subject
Lower probability
on the GRADE evidence scale
This study watched 18 people with Alzheimer's take creatine for 8 weeks and noticed their muscles got a little bigger. But we don't know if the creatine caused it—maybe they moved more, or their bodies changed naturally. It's like noticing your shoes got dirtier after walking outside—you can't be sure if it was the dirt or the walk that made it happen.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Used objective imaging (ultrasonography) to measure muscle size
- Used validated software (ImageJ) for measurements
- Reported statistical significance with p-values
Weaknesses
- No control group
- No randomization
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study didn't have a comparison group or hide who was taking the supplement, so it's like taking a selfie without checking if the lighting is fair. That makes it hard to trust that the results are really because of the creatine and not something else. Good studies compare people and hide who gets what to avoid bias.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
15 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=18)+1.7/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 531 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a single-arm study with no control group, no randomization, and no blinding. Changes observed could be due to time, placebo effects, or other unmeasured factors, not necessarily creatine supplementation.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding sources were disclosed; authors are affiliated with academic institutions and no industry ties are evident.
The study lacks a declared funding statement or conflict of interest disclosure. However, all authors are affiliated with academic institutions (University of Kansas), and there is no indication of industry involvement, sponsorship, or control over the study design, analysis, or publication.